Next-Generation Biomanufacturing Market Analysis

Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Hormones)

Monoclonal antibodies segment in the next-generation biomanufacturing market is expected to hold a share of 48% during the forecast period. Throughout the forecast period, the global market for next-generation biomanufacturing is predicted to witness a consistently rapid expansion in the monoclonal antibodies segment. This is so because monoclonal antibodies are a class of biopharmaceuticals that are routinely employed to treat a wide range of illnesses. The production of monoclonal antibodies, which has a number of advantages compared to traditional manufacturing methods, is increasing with the use of next-generation biotechnological techniques. Furthermore, the development of monoclonal antibodies in a variety of diseases is being increasingly pursued by companies. For instance, Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is developing a novel therapeutic for the treatment of Alzheimer's disease that targets soluble amyloid beta oligomers. The company recently announced that it had won the prestigious "Monoclonal Antibody Solution of the Year" award from the BioTech Breakthrough Awards program. In addition, the time it takes for mAbs to reach the market can be reduced by next-generation biotechnologies, which allow for a faster and more efficient manufacturing process.

End-user (Biopharmaceutical Companies, Research Institutions, Contract Research Organizations)

Biopharmaceutical companies segment in the next-generation biomanufacturing market is poised to hold a share of 44% during the forecast period. This is because next-generation biomanufacturing strategies are needed for customized medication and protein production, which are the current areas of concentration for biopharmaceutical businesses. Biologic medications play a major role in the quickly expanding field of personalized medicine. As per a report, personalized medications made up 21% of all FDA-approved novel molecular entities in 2014; by 2022, however, that percentage had risen to 34%. It is anticipated that biopharmaceutical companies will need to modify their manufacturing processes to fulfill the demands of this industry as the desire for personalized medication continues to rise. This might involve creating personalized biologic medications for each patient using cutting-edge biomanufacturing methods.

Our in-depth analysis of the global next-generation biomanufacturing market includes the following segments: